Janssen's Incivo offers mixed bag of benefits, says IQWiG
This article was originally published in Scrip
Executive Summary
Janssen-Cilag's novel hepatitis C protease inhibitor, Incivo (telaprevir), in combination with peginterferon alfa and ribavirin, potentially offers a “hint” of added benefit for some patients, and more certain benefits for others over current standard therapy (peginterferon alfa and ribavirin), says IQWiG, the German HTA institute. However, it claims that the extent of those benefits is unquantifiable, largely because it does not view sustained virological response (SVR) as a formal patient outcome.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.